Back to Journals » ImmunoTargets and Therapy » Volume 9

Targeting IL-4 for the Treatment of Atopic Dermatitis

Authors Chiricozzi A, Maurelli M, Peris K, Girolomoni G

Received 27 August 2020

Accepted for publication 16 September 2020

Published 29 September 2020 Volume 2020:9 Pages 151—156


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Michael Shurin

Andrea Chiricozzi,1,2 Martina Maurelli,3 Ketty Peris,1,2 Giampiero Girolomoni3

1Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 3Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy

Correspondence: Andrea Chiricozzi
Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy
Tel +39-339 5668320
Fax +39-0761-571321

Abstract: Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.

Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]